Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort ascending Project Status Date Submission Received Date Recommendation Issued
Maviret glecaprevir / pibrentasvir Hepatitis C, chronic CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Epclusa sofosbuvir / velpatasvir Hepatitis C, chronic CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Trelegy Ellipta fluticasone furoate/umeclidinium bromide/vilanterol trifenatate Asthma, maintenance CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xolair omalizumab Chronic rhinosinusitis with nasal polyps CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Nucala mepolizumab Asthma, severe eosinophilic (pediatric) CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Tafinlar and Mekinist dabrafenib and trametinib Pediatric glioma with a BRAF V600E CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Darzalex daratumumab Multiple myeloma, eligible for autologous stem cell transplant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Victoza liraglutide Diabetes Mellitus, Type 2 (pediatric) CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Viibryd vilazodone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed